Compare Stocks: HUMA, MNPR, SVA, and NGNE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HUMA Humacyte	$0.56 -2.0%	$0.63	$0.53 ▼ $2.55	$157.98M	2.45	4.54 million shs	2.62 million shs
MNPR Monopar Therapeutics	$85.24 -4.1%	$110.21	$50.07 ▼ $124.82	$596.31M	1.49	140,176 shs	105,822 shs
NGNE Neurogene	$28.31 -9.4%	$35.71	$15.93 ▼ $43.66	$625.36M	1.69	310,819 shs	200,066 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HUMA Humacyte	-2.00%	-4.83%	-18.24%	-21.35%	-66.83%
MNPR Monopar Therapeutics	-4.05%	-11.64%	-25.04%	-2.78%	+16.70%
NGNE Neurogene	-9.41%	-11.78%	-26.30%	-11.61%	+64.12%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HUMA Humacyte	$0.56 -2.0%	$0.63	$0.53 ▼ $2.55	$157.98M	2.45	4.54 million shs	2.62 million shs
MNPR Monopar Therapeutics	$85.24 -4.1%	$110.21	$50.07 ▼ $124.82	$596.31M	1.49	140,176 shs	105,822 shs
NGNE Neurogene	$28.31 -9.4%	$35.71	$15.93 ▼ $43.66	$625.36M	1.69	310,819 shs	200,066 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HUMA Humacyte	-2.00%	-4.83%	-18.24%	-21.35%	-66.83%
MNPR Monopar Therapeutics	-4.05%	-11.64%	-25.04%	-2.78%	+16.70%
NGNE Neurogene	-9.41%	-11.78%	-26.30%	-11.61%	+64.12%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HUMA Humacyte	2.71	Moderate Buy	$6.54	1,073.81% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$121.36	42.38% Upside
NGNE Neurogene	2.83	Moderate Buy	$83.67	195.54% Upside
SVA Sinovac Biotech	3.00	Buy	$1.00	-84.54% Downside

Current Analyst Ratings Breakdown

Latest HUMA, MNPR, SVA, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$128.00 ➝ $145.00
9/8/2026	SVA Sinovac Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00 ➝ $1.00
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
8/12/2026	NGNE Neurogene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$69.00 ➝ $81.00
8/12/2026	MNPR Monopar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$117.00 ➝ $133.00
8/12/2026	NGNE Neurogene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$180.00 ➝ $166.00

(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HUMA Humacyte	$2.04M	75.89	N/A	N/A	$0.02 per share	27.87
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
NGNE Neurogene	$930K	609.12	N/A	N/A	$17.10 per share	1.66
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-45.10%	-41.00%	11/12/2026 (Estimated)
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest HUMA, MNPR, SVA, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HUMA Humacyte	2.07	6.21	5.74
MNPR Monopar Therapeutics	N/A	33.56	33.56
NGNE Neurogene	N/A	10.65	10.64
SVA Sinovac Biotech	0.04	6.07	5.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HUMA Humacyte	44.71%
MNPR Monopar Therapeutics	1.83%
NGNE Neurogene	52.37%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
HUMA Humacyte	3.10%
MNPR Monopar Therapeutics	9.70%
NGNE Neurogene	11.68%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
MNPR Monopar Therapeutics	22	6.71 million	6.06 million	Not Optionable
NGNE Neurogene	131	20.01 million	17.67 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable

HUMA, MNPR, SVA, and NGNE Headlines

Recent News About These Companies

Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA

July 21, 2026 | benzinga.com

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

July 15, 2026 | businesswire.com

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

July 12, 2026 | businesswire.com

Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report

June 15, 2026 | tipranks.com

Sinovac Biotech Ltd.

June 8, 2026 | edition.cnn.com

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

June 5, 2026 | businesswire.com

Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance

May 29, 2026 | tipranks.com

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

May 29, 2026 | businesswire.com

SVA Share News Today

May 16, 2026 | uk.investing.com

SINOVAC Reports Unaudited First Half of 2025 Financial Results

May 8, 2026 | businesswire.com

Sinovac Biotech Delays Key Annual 20-F Filing

April 30, 2026 | tipranks.com

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

April 30, 2026 | businesswire.com

Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.

March 28, 2026 | tennessean.comT

Sinovac Controlling Shareholders Escape Investor Disclosure Suit

February 25, 2026 | news.bloomberglaw.comN

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

January 22, 2026 | businesswire.com

Sinovac Biotech receives Nasdaq notification regarding late filing of FY25

January 4, 2026 | msn.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | financialpost.comF

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

January 4, 2026 | businesswire.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | businesswire.com

Antigua High Court gives Sinovac Biotech board control until trial

December 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HUMA, MNPR, SVA, and NGNE Company Descriptions

Humacyte NASDAQ:HUMA

$0.56 -0.01 (-2.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.00 (+0.48%)

As of 09/25/2026 07:58 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Monopar Therapeutics NASDAQ:MNPR

$85.24 -3.60 (-4.05%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$85.37 +0.13 (+0.15%)

As of 09/25/2026 07:32 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Neurogene NASDAQ:NGNE

$28.31 -2.94 (-9.41%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$28.48 +0.17 (+0.60%)

As of 09/25/2026 07:49 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 09/25/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, MNPR, SVA, and NGNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, MNPR, SVA, and NGNE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, MNPR, SVA, and NGNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, MNPR, SVA, and NGNE Company Descriptions

Humacyte NASDAQ:HUMA

Monopar Therapeutics NASDAQ:MNPR

Neurogene NASDAQ:NGNE

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, MNPR, SVA, and NGNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, MNPR, SVA, and NGNE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, MNPR, SVA, and NGNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, MNPR, SVA, and NGNE Company Descriptions

Humacyte NASDAQ:HUMA

Monopar Therapeutics NASDAQ:MNPR

Neurogene NASDAQ:NGNE

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools